CN107050145A - Application of the Black Box Tracing fruit extract in treatment antiaging agent is prepared - Google Patents
Application of the Black Box Tracing fruit extract in treatment antiaging agent is prepared Download PDFInfo
- Publication number
- CN107050145A CN107050145A CN201710305640.7A CN201710305640A CN107050145A CN 107050145 A CN107050145 A CN 107050145A CN 201710305640 A CN201710305640 A CN 201710305640A CN 107050145 A CN107050145 A CN 107050145A
- Authority
- CN
- China
- Prior art keywords
- fruit extract
- black box
- aging
- box tracing
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 35
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 34
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims 1
- 239000002250 absorbent Substances 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000005057 refrigeration Methods 0.000 claims 1
- 230000009758 senescence Effects 0.000 claims 1
- 238000004506 ultrasonic cleaning Methods 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 30
- 230000032683 aging Effects 0.000 description 26
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 18
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 18
- 241001444063 Aronia Species 0.000 description 15
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 9
- 229960003638 dopamine Drugs 0.000 description 9
- 229960002748 norepinephrine Drugs 0.000 description 9
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 240000005662 Aronia melanocarpa Species 0.000 description 7
- 235000007425 Aronia melanocarpa Nutrition 0.000 description 7
- 230000005778 DNA damage Effects 0.000 description 7
- 231100000277 DNA damage Toxicity 0.000 description 7
- 210000005013 brain tissue Anatomy 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000000971 hippocampal effect Effects 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007087 memory ability Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000019194 Sorbus aucuparia Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- RKWHWFONKJEUEF-WVXKDWSHSA-O cyanidin 3-O-beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 RKWHWFONKJEUEF-WVXKDWSHSA-O 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000006414 serbal de cazadores Nutrition 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 241000245566 Adenocarpus Species 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- ORTBMTXABUAMJS-VGEDXCMYSA-N Cyanidin 3-arabinoside Chemical compound [Cl-].O[C@H]1[C@H](O)[C@H](O)CO[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 ORTBMTXABUAMJS-VGEDXCMYSA-N 0.000 description 1
- KUCVMQMKRICXJC-FBVAEJEDSA-O Cyanidin 3-arabinoside Natural products O([C@H]1[C@@H](O)[C@@H](O)[C@H](O)CO1)c1c(-c2cc(O)c(O)cc2)[o+]c2c(c(O)cc(O)c2)c1 KUCVMQMKRICXJC-FBVAEJEDSA-O 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000859758 Homo sapiens Cartilage-associated protein Proteins 0.000 description 1
- 101000916686 Homo sapiens Cytohesin-interacting protein Proteins 0.000 description 1
- 101000726740 Homo sapiens Homeobox protein cut-like 1 Proteins 0.000 description 1
- 101000761460 Homo sapiens Protein CASP Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 101000761459 Mesocricetus auratus Calcium-dependent serine proteinase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- 102100024933 Protein CASP Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241001092391 Sorbus Species 0.000 description 1
- 235000014459 Sorbus Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000001490 effect on brain Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000007853 structural degeneration Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
技术领域technical field
本发明属于保健食品和药物的用途领域,具体地涉及黑果腺肋花楸果实提取物在制备具有抗衰老作用的药品或保健品中的应用。The invention belongs to the application field of health food and medicine, and in particular relates to the application of the fruit extract of Aronia nigricarpa in the preparation of anti-aging medicine or health care product.
背景技术Background technique
衰老,是生物随着时间的推移,自发的必然过程,它是复杂的自然现象,表现为结构的退行性变和机能的衰退,适应性和抵抗力减退。衰老一直是生命过程中的核心环节,也是影响整个人类社会健康发展的重要问题。抗衰老药物能在一定程度上延缓衰老,促进身体健康,在遗传因素决定的寿限内,保持较好智力和体力。目前抗衰老药物可以分为传统中药和现代药物两大类。例如脑益嗪、脑复康、西比灵等药物能改善脑血液循环,促进脑细胞代谢,但化学合成的药物,其成本大,毒性大,副作用强,会影响内分泌功能和凝血机制,产生疲乏、烦躁不安、血压升高、水肿、失眠等副作用。因此,从天然植物中寻找具有生物活性的、抗衰老作用的物质应用于医药、食品和保健品中具有重要的意义。Aging is a natural and inevitable process of organisms with the passage of time. It is a complex natural phenomenon, manifested as structural degeneration, functional decline, and decreased adaptability and resistance. Aging has always been the core link in the life process, and it is also an important issue that affects the healthy development of the entire human society. Anti-aging drugs can delay aging to a certain extent, promote physical health, and maintain better intelligence and physical strength within the life span determined by genetic factors. At present, anti-aging drugs can be divided into two categories: traditional Chinese medicine and modern medicine. For example, drugs such as Naoyizine, Naofukang, and Sibeline can improve cerebral blood circulation and promote brain cell metabolism, but chemically synthesized drugs have high cost, high toxicity, and strong side effects, which will affect endocrine function and blood coagulation mechanism. Fatigue, irritability, increased blood pressure, edema, insomnia and other side effects. Therefore, it is of great significance to find biologically active and anti-aging substances from natural plants for use in medicine, food and health care products.
黑果腺肋花楸(Aornia mealnocarpa Elliot)又称野樱莓、不老莓,是集食用、药用、园林和生态价值于一身的珍贵树种。原产于北美东北部,为近年来辽宁省主要引进经济树种。Aornia mealnocarpa Elliot, also known as Aronberry and Elliot, is a precious tree species with edible, medicinal, garden and ecological values. Native to northeastern North America, it is the main economic tree species introduced in Liaoning Province in recent years.
发明内容Contents of the invention
本发明以寻求新型高效的抗衰老药品或保健品的开发利用为目的,提出了黑果腺肋花楸果实提取物在制备抗衰老作用的药品或保健品中的应用。The present invention aims to seek the development and utilization of new and efficient anti-aging medicines or health care products, and proposes the application of Aronia fruit extracts in the preparation of anti-aging medicines or health care products.
本发明采用黑果腺肋花楸果实提取物作为原料,单用或与其他具有抗衰老作用的药物组合,按常规制剂的制备方法,制备成适合口服的任何剂型的具有抗衰老作用的药品或保健品,如口服液,片剂,胶囊,颗粒剂,或其它针剂剂型。The present invention adopts the fruit extract of Aronia nigricarpa as a raw material, which is used alone or in combination with other drugs with anti-aging effects, and is prepared into any dosage form of anti-aging drugs suitable for oral administration or in combination with other drugs with anti-aging effects. Health care products, such as oral liquids, tablets, capsules, granules, or other injection dosage forms.
本发明采用的是黑果腺肋花楸果实醇提提取物,以D-半乳糖诱导的方式诱导小鼠快速衰老,通过衰老模型小鼠体内实验得出,黑果腺肋花楸果实提取物可以抑制衰老小鼠脑指数和学习记忆能力的下降,以及脑组织内单胺神经递质去甲状腺肾上腺素(NE)、多巴胺(DA)、5-羟色胺(5-HT)含量的下降,并维持衰老小鼠海马组织结构的完整及良好的形态;抑制衰老过程中DNA的损伤。因此,黑果腺肋花楸果实提取物具有抗衰老的功效,是开发新型高效的天然抗衰老药物或保健品的一个好选择。What the present invention adopts is the fruit extract of Aronia nigriflora, which is induced by D-galactose to induce rapid aging of mice. It is obtained through the in vivo experiment of aging model mice that the fruit extract of Aronia nigriflora It can inhibit the decline of brain index and learning and memory ability in aging mice, as well as the decline of the content of monoamine neurotransmitters norepinephrine (NE), dopamine (DA) and 5-hydroxytryptamine (5-HT) in brain tissue, and maintain Integrity and good shape of hippocampus tissue structure in aging mice; inhibition of DNA damage during aging. Therefore, the fruit extract of Aronia nigra has anti-aging effects, and it is a good choice for developing new and efficient natural anti-aging drugs or health products.
附图说明Description of drawings
图1是各组小鼠脑系数的比较结果。Figure 1 shows the comparison results of the brain coefficients of mice in each group.
图2是各组小鼠单胺神经递质类物质(去甲状腺肾上腺素、多巴胺、5-羟色胺)水平比较。Figure 2 is a comparison of the levels of monoamine neurotransmitters (norepinephrine, dopamine, 5-hydroxytryptamine) in mice in each group.
图3是各组小鼠海马组织HE染色情况。Figure 3 is the HE staining of the hippocampal tissues of mice in each group.
图4是各组小鼠脑组织细胞DNA损伤情况比较图。Fig. 4 is a comparison chart of DNA damage in brain tissue cells of mice in each group.
图5是各组小鼠脑组织细胞DNA损伤情况数据统计图。Fig. 5 is a statistical diagram of DNA damage data in brain tissue cells of mice in each group.
具体实施方式detailed description
实施例1 黑果腺肋花楸果实提取物在制备治疗抗衰老药物中的应用Example 1 Application of Aronia nigra fruit extract in the preparation of anti-aging drugs
(一)制备方法(1) Preparation method
黑果腺肋花楸果实提取物的制备:称取黑果腺肋花楸果实100g,用60%的乙醇在60-70℃浸泡1h,放入超声清洗器中超声30min,连续2次,经大孔吸附树脂AB-8纯化后,再用旋转蒸发仪浓缩提取液,经过真空冷冻干燥得黑果腺肋花楸果实提取物干粉。Preparation of Aronia fruit extract: Weigh 100 g of Aronia fruit extract, soak it in 60% ethanol at 60-70°C for 1 hour, put it into an ultrasonic cleaner for 30 minutes, and do so twice in a row. After the macroporous adsorption resin AB-8 is purified, the extract is concentrated by a rotary evaporator, and vacuum freeze-dried to obtain a dry powder of the Aronia fruit extract.
经检测,提取物干粉主要含有47.6%的矢车菊素阿拉伯糖苷(cyanidin 3-arabinoside)和46.4%的矢车菊素半乳糖苷(cyanidin 3-galactoside)成分。After testing, the dry powder of the extract mainly contains 47.6% of cyanidin 3-arabinoside and 46.4% of cyanidin 3-galactoside.
(二)药效试验(2) drug efficacy test
动物饲养及处理:实验动物饲养1周以适应本实验室条件,分笼饲养,室内无菌消毒,每两天换一次垫料。控制实验室光照12h明-12h暗,室内温度为20±1℃,湿度为55±10%。Animal feeding and handling: The experimental animals were fed for 1 week to adapt to the conditions of the laboratory, kept in separate cages, sterilized indoors, and the litter was changed every two days. The control laboratory light is 12h bright-12h dark, the indoor temperature is 20±1°C, and the humidity is 55±10%.
实验动物分组:雄性小鼠60只,体重30±2g,随机分为4组如下,每组15只。Grouping of experimental animals: 60 male mice, weighing 30±2g, were randomly divided into 4 groups as follows, 15 in each group.
(1)正常对照组(N);(1) normal control group (N);
(2)衰老模型组(M);(2) aging model group (M);
(3)给药组:花楸果实提取物组15mg/kg(每日)(L);(3) Administration group: Rowan fruit extract group 15mg/kg (daily) (L);
(4)给药组:花楸果实提取物组30mg/kg(每日)(H)(4) Administration group: Rowan fruit extract group 30mg/kg (daily) (H)
正常对照组15只小鼠皮下注射生理盐水,其余小鼠注射D-半乳糖(150mg/kg),每日一次,持续8周。造模的同时进行给药,除正常对照组、衰老模型组小鼠给予生理盐水饮水外,给药组小鼠分别给予花楸果实提取物15mg/kg和30mg/kg灌胃,每周称量并记录小鼠体重。实验8周时,进行检测。In the normal control group, 15 mice were subcutaneously injected with normal saline, and the rest were injected with D-galactose (150 mg/kg), once a day for 8 weeks. Administration was administered while the model was being established. In addition to the normal control group and the aging model group mice were given normal saline drinking water, the mice in the administration group were given 15 mg/kg and 30 mg/kg of Sorbus fruit extract by intragastric administration, and weighed weekly. And record the body weight of the mice. At the 8th week of the experiment, the test was carried out.
1.水迷宫实验:各组小鼠在水迷宫实验中潜伏期与穿越次数的比较结果见表1。1. Water maze test: Table 1 shows the comparison results of the incubation period and the number of crossing times in the water maze test for mice in each group.
表1 各组小鼠在水迷宫实验中潜伏期与穿越次数的比较Table 1 Comparison of the latency and crossing times of mice in each group in the water maze test
ap<0.01,vs.Control;bp<0.01,vs.Model(给药八周后)。 a p<0.01, vs. Control; b p<0.01, vs. Model (after eight weeks of administration).
由表1可以看出,水迷宫实验发现,衰老模型组小鼠的平台逃避潜伏期时间明显高于正常组,黑果腺肋花楸果实提取物给药能够显著减小平台逃避潜伏期(vs.模型组p<0.01);模型组小鼠平台穿越次数显著低于正常对照组(p<0.01),给药组能够显著增加平台穿越次数(vs.模型组p<0.01),而且给药组H组显著高于正常对照组(p<0.01)。实验结果说明黑果腺肋花楸果实提取物对小鼠衰老过程中学习记忆能力的下降具有显著的改善作用且呈剂量相关性。It can be seen from Table 1 that the water maze experiment found that the platform escape latency time of the mice in the aging model group was significantly higher than that of the normal group, and the administration of the Aronia fruit extract could significantly reduce the platform escape latency (vs. group p<0.01); the number of platform crossings in the model group was significantly lower than that in the normal control group (p<0.01), and the administration group could significantly increase the number of platform crossings (vs. model group p<0.01), and the administration group H group Significantly higher than the normal control group (p<0.01). The experimental results show that the fruit extract of Aronia nigra can significantly improve the decline of learning and memory ability in the aging process of mice, and it is dose-related.
2.采血后处死小鼠,收集脑组织并称重,计算脑系数。脑系数的比较结果见图1。2. The mice were sacrificed after blood collection, the brain tissue was collected and weighed, and the brain coefficient was calculated. The comparison results of the brain coefficients are shown in Figure 1.
如图1所示,衰老模型组小鼠脑系数明显低于正常组(8.98vs 10.96,p<0.01),黑果腺肋花楸果实提取物给药能干预衰老引起的脑系数降低,相较于衰老模型组,给药组H可以显著抑制小鼠脑系数的降低(10.70,p<0.01)。实验结果说明黑果腺肋花楸果实提取物对于小鼠衰老过程中脑萎缩具有显著的干预作用且呈剂量相关性。As shown in Figure 1, the brain coefficient of mice in the aging model group was significantly lower than that of the normal group (8.98vs 10.96, p<0.01), and the administration of Aronia nigricarpa fruit extract could interfere with the decrease of brain coefficient caused by aging, compared with In the aging model group, administration group H can significantly inhibit the reduction of the brain coefficient of mice (10.70, p<0.01). The experimental results show that Aronia fruit extract has a significant intervention effect on brain atrophy in the aging process of mice in a dose-dependent manner.
3.检测脑组织内单胺神经递质去甲状腺肾上腺素(NE)、多巴胺(DA)、5-羟色胺(5-HT)含量,结果见图2。3. Detect the content of monoamine neurotransmitters norepinephrine (NE), dopamine (DA) and 5-hydroxytryptamine (5-HT) in the brain tissue, the results are shown in Figure 2.
如图2所示,衰老模型组小鼠的去甲状腺肾上腺素、多巴胺、5-羟色胺含量明显低于正常组,黑果腺肋花楸果实提取物给药可以提高D-半乳糖所致的三种单胺神经递质含量下降,且其对多巴胺含量的提高具有显著性(给药组L为p<0.05,给药组H为p<0.001),但去甲状腺肾上腺素和5-羟色胺的含量并无显著性变化。实验结果说明黑果腺肋花楸果实提取物对小鼠衰老过程中情感记忆衰退具有一定的干预作用,并且呈剂量相关性。As shown in Figure 2, the contents of noradrenaline, dopamine, and 5-hydroxytryptamine in the mice in the aging model group were significantly lower than those in the normal group, and the administration of the fruit extract of Aronia nigricarpa can increase the levels of three levels induced by D-galactose. The content of a monoamine neurotransmitter decreased, and it significantly increased the content of dopamine (p<0.05 in the administration group L, p<0.001 in the administration group H), but the contents of noradrenaline and serotonin There was no significant change. The experimental results show that Aronia fruit extract has a certain intervention effect on the decline of emotional memory in the aging process of mice, and it is dose-related.
4.HE染色观察衰老小鼠海马组织的结构和形态,结果见图3。4. HE staining was used to observe the structure and morphology of the hippocampal tissue of aging mice, and the results are shown in Figure 3.
如图3所示,衰老模型组小鼠海马组织细胞数量明显少于正常对照组小鼠,且排列稀疏,结构不规则。黑果腺肋花楸果实提取物给药能够抑制衰老小鼠海马细胞数量的减少,且能够维持细胞形态结构稳定,抑制变性现象的发生。实验结果说明黑果腺肋花楸果实提取物能够维持衰老小鼠海马组织结构的完整及良好的形态。As shown in Figure 3, the number of hippocampal tissue cells in the aging model group mice was significantly less than that in the normal control group mice, and the arrangement was sparse and the structure was irregular. The administration of Aronia nigra fruit extract can inhibit the reduction of the number of hippocampal cells in aging mice, maintain the stability of cell morphology and structure, and inhibit the occurrence of degeneration. The experimental results show that the fruit extract of Aronia nigra can maintain the integrity and good shape of the hippocampal tissue structure of aging mice.
5.采用彗星实验检测脑组织DNA损伤状况,CASP分析软件测算(尾长(TailLength)、尾DNA含量(Tail DNA%)、尾矩(Tail Moment)、Olive尾矩(Olive Tail Moment,OTM)等相关参数。结果见图4和图5。5. The comet test was used to detect DNA damage in brain tissue, and CASP analysis software was used to calculate (Tail Length, Tail DNA content (Tail DNA%), Tail Moment, Olive Tail Moment (OTM), etc. Related parameters. The results are shown in Figure 4 and Figure 5.
如图4和图5所示,与正常组相比较,衰老模型组的脑细胞DNA明显有拖尾现象,且二者的尾长、尾部DNA量、尾炬及Olive尾炬都呈现显著性差异(p<0.001)。黑果腺肋花楸果实提取物给药可以抑制DNA损伤的积累且呈剂量相关性,具有显著性差异(p<0.001)。实验结果说明黑果腺肋花楸果实提取物对细胞DNA损伤具有显著的抑制作用。As shown in Figure 4 and Figure 5, compared with the normal group, the DNA of brain cells in the aging model group has obvious tailing phenomenon, and there are significant differences in the length of the tail, the amount of DNA in the tail, the tail and the Olive tail. (p<0.001). The administration of Aronia nigra fruit extract can inhibit the accumulation of DNA damage in a dose-related manner, with significant differences (p<0.001). The experimental results showed that the fruit extract of Aronia adenocarpus had a significant inhibitory effect on cellular DNA damage.
结果表明黑果腺肋花楸果实提取物可以抑制衰老小鼠脑指数和学习记忆能力的下降,以及脑组织内单胺神经递质去甲状腺肾上腺素(NE)、多巴胺(DA)、5-羟色胺(5-HT)含量的下降,并维持衰老小鼠海马组织结构的完整及良好的形态;抑制衰老过程中DNA的损伤。说明其具有抗衰老的功效,且呈剂量相关性。结论:黑果腺肋花楸果实提取物能够减少年龄相关性变化,提高老年期间的生存质量,抗衰老的能力强,是开发新型高效的天然抗衰老药物或保健品的一个好选择。The results showed that the fruit extract of Aronia nigra can inhibit the decline of brain index and learning and memory ability in aging mice, as well as the monoamine neurotransmitters norepinephrine (NE), dopamine (DA), and serotonin in brain tissue. The decline of (5-HT) content, and maintain the integrity and good shape of the hippocampus tissue structure of aging mice; inhibit DNA damage in the aging process. It shows that it has anti-aging effect, and it is dose-related. Conclusion: Aronia fruit extract can reduce age-related changes, improve the quality of life in old age, and has strong anti-aging ability. It is a good choice for the development of new and efficient natural anti-aging drugs or health products.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710305640.7A CN107050145A (en) | 2017-05-03 | 2017-05-03 | Application of the Black Box Tracing fruit extract in treatment antiaging agent is prepared |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710305640.7A CN107050145A (en) | 2017-05-03 | 2017-05-03 | Application of the Black Box Tracing fruit extract in treatment antiaging agent is prepared |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107050145A true CN107050145A (en) | 2017-08-18 |
Family
ID=59597514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710305640.7A Pending CN107050145A (en) | 2017-05-03 | 2017-05-03 | Application of the Black Box Tracing fruit extract in treatment antiaging agent is prepared |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107050145A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108409703A (en) * | 2018-06-07 | 2018-08-17 | 中国农业大学 | A method for separating anthocyanins with anti-aging effect by simulating moving bed |
CN110584107A (en) * | 2019-09-19 | 2019-12-20 | 宝健(北京)生物技术有限公司 | Five-element five-color multi-azimuth aging-delaying composition and preparation containing same |
CN111909227A (en) * | 2020-08-24 | 2020-11-10 | 中国科学院新疆理化技术研究所 | Preparation method of aronia melanocarpa pomace anthocyanin extract |
CN112190618A (en) * | 2020-11-02 | 2021-01-08 | 山东理工大学 | Application of aronia melanocarpa leaf polyphenol extract in preparation of antidepressant drugs |
CN112273649A (en) * | 2020-11-03 | 2021-01-29 | 深圳市新靶向生物科技有限公司 | A kind of antioxidant, anti-aging composition and preparation method and application |
CN113115860A (en) * | 2021-04-01 | 2021-07-16 | 广西壮族自治区农业科学院 | Application and use method of aronia melanocarpa fruit residues |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105106351A (en) * | 2015-09-10 | 2015-12-02 | 廊坊弘祥隆生物技术有限公司 | Production method of aronia melanocarpa extract |
CN105968080A (en) * | 2016-05-31 | 2016-09-28 | 辽宁富康源黑果花楸科技开发有限公司 | Method for extracting anthocyanidin from black chokeberries |
-
2017
- 2017-05-03 CN CN201710305640.7A patent/CN107050145A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105106351A (en) * | 2015-09-10 | 2015-12-02 | 廊坊弘祥隆生物技术有限公司 | Production method of aronia melanocarpa extract |
CN105968080A (en) * | 2016-05-31 | 2016-09-28 | 辽宁富康源黑果花楸科技开发有限公司 | Method for extracting anthocyanidin from black chokeberries |
Non-Patent Citations (2)
Title |
---|
李梦莎: "响应面法优化超声提取黑果腺肋花楸花色苷工艺的研究", 《中国酿造》 * |
郑悦等: "黑果花楸花色苷提取、纯化工艺研究", 《北京林业大学学报》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108409703A (en) * | 2018-06-07 | 2018-08-17 | 中国农业大学 | A method for separating anthocyanins with anti-aging effect by simulating moving bed |
CN108409703B (en) * | 2018-06-07 | 2023-02-28 | 中国农业大学 | A method for separating anthocyanins with anti-aging effect by simulating moving bed |
CN110584107A (en) * | 2019-09-19 | 2019-12-20 | 宝健(北京)生物技术有限公司 | Five-element five-color multi-azimuth aging-delaying composition and preparation containing same |
CN111909227A (en) * | 2020-08-24 | 2020-11-10 | 中国科学院新疆理化技术研究所 | Preparation method of aronia melanocarpa pomace anthocyanin extract |
CN112190618A (en) * | 2020-11-02 | 2021-01-08 | 山东理工大学 | Application of aronia melanocarpa leaf polyphenol extract in preparation of antidepressant drugs |
CN112190618B (en) * | 2020-11-02 | 2023-02-03 | 山东理工大学 | Application of aronia melanocarpa leaf polyphenol extract in preparation of antidepressant drugs |
CN112273649A (en) * | 2020-11-03 | 2021-01-29 | 深圳市新靶向生物科技有限公司 | A kind of antioxidant, anti-aging composition and preparation method and application |
CN112273649B (en) * | 2020-11-03 | 2022-06-21 | 深圳市新靶向生物科技有限公司 | A kind of antioxidant, anti-aging composition and preparation method and application |
CN113115860A (en) * | 2021-04-01 | 2021-07-16 | 广西壮族自治区农业科学院 | Application and use method of aronia melanocarpa fruit residues |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107050145A (en) | Application of the Black Box Tracing fruit extract in treatment antiaging agent is prepared | |
CN102872206B (en) | Traditional Chinese medicine compound capable of improving immunity, resisting fatigue and improving sexual function | |
CN103168919B (en) | Feed additive for enhancing immunity and promoting growth and feed | |
CN102940722B (en) | A kind ofly treat Chinese medicine composition of fowl bacterial disease and preparation method thereof | |
CN105641031A (en) | Compound pharmaceutical composition for strengthening body resistance and removing toxin, use and feed thereof | |
CN108310080A (en) | Application of the Black Box Tracing anthocyanin in preparing anti-hepatic fibrosis drug or health products | |
CN104208294B (en) | It is a kind of to be used to treat Chinese medicine composition of piglet yellow-white dysentery and preparation method thereof | |
CN104436142B (en) | A kind of Chinese medicine composition for treating pig epidemic diarrhea | |
CN101715893B (en) | Pure natural piglet immunological enhancement feed additive and application thereof | |
CN104644757A (en) | Traditional Chinese medicine oral liquid for treating avian influenza and preparation method thereof | |
CN104222522B (en) | It is a kind of to prevent chicken feed of bamboo silk white diarrhea and preparation method thereof | |
CN103550354B (en) | Compound stomach-invigorating and intestine-treating granules for fishes and preparation method thereof | |
CN103142683B (en) | Be used for the treatment of Chinese medicinal perfusion liquid containing Herba Sophorae alopecuroidis total alkali of bovine mastitis and endometritis and preparation method thereof | |
CN106511675A (en) | Medicine for preventing and treating poultry diseases and preparation method of medicine | |
CN101120750B (en) | Method for preparing ginkgo bee product | |
CN106619887B (en) | Compound traditional Chinese medicine preparation for inhibiting and killing schbert unicellular bacteria, preparation method and application thereof | |
CN101829257B (en) | Traditional Chinese medicine oral liquid for treating chicken colibacillosis and preparation method thereof | |
CN113425697A (en) | Preparation and preliminary pharmaceutical evaluation method of compound qi-tonifying intestine-moistening capsule | |
CN102416050B (en) | Veterinary medicinal preparation for treating colibacillosis and preparation method thereof | |
CN101664485A (en) | Traditional Chinese medicine for treating respiratory disease of livestock and preparation method thereof | |
CN104906146B (en) | Medical applications of the peacilomyce hepiahi bacterium strain PH40 in depression | |
CN116942729B (en) | Chinese herbal medicine composition, and preparation method, feed and application thereof | |
CN105748873A (en) | Veterinary traditional Chinese medicine particle for treating livestock and poultry respiratory tract infection | |
CN104800471B (en) | It is a kind of to be used to treat Chinese medicine composition of urarthritis and its preparation method and application | |
CN115006496B (en) | Chinese herbal medicine composition for treating pneumonia of foxes, raccoon dogs and martens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170818 |
|
RJ01 | Rejection of invention patent application after publication |